C4X Discovery's () Clive Dix talks Proactive London's Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln.
The group will receive €7mln upfront, plus €11mln in pre-clinical payments.
The deal is for their oral IL-17A inhibitor programme, currently IL-17 monoclonal antibodies are administered by injection. Having an oral version represents a significant breakthrough.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE